Corbus Pharmaceuticals (CRBP) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, gaining 42.9% versus a loss of 60.7%. Over five years, CRBP leads with a -82.8% price change compared with -97.8% for PYPD. Corbus Pharmaceuticals is the larger company by market cap ($107.7 million vs $101.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | PYPD |
|---|---|---|
| Share price | $5.57 | $5.01 |
| Market cap | $107.73M | $101.76M |
| 1-day change | +5.69% | +2.24% |
| YTD return | -35.26% | +12.90% |
| 1-year return | -60.73% | +42.86% |
| 5-year return | -82.78% | -97.83% |
| EPS (TTM) | $-6.11 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $5.73 |
| 52-week low | $5.13 | $3.06 |
| Distance from 52-week high | -72.91% | -12.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +510.95% | +134.53% |
| Average volume | 756.54K | 176.73K |
| Shares outstanding | 19.34M | 20.31M |
| Employees | 36 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed CRBP by 103.6 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
CRBP vs PYPD FAQ
Which is bigger, Corbus Pharmaceuticals or PolyPid?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $107.73M compared with $101.76M for PolyPid (PYPD).
Which stock has performed better over the past year, CRBP or PYPD?
PYPD returned +42.86% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and PolyPid in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Corbus Pharmaceuticals and Medical/Dental Instruments for PolyPid.